EUVIMEDEUVIMED entdecken
Crossref

METTL3-Mediated m 6 A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis

Siyuan Fu, Dapeng Sun, Zongyan Wang, Peng Zhu, Wenbin Ding, Jian Huang, Xinggang Guo, Yun Yang, Fangming Gu iD

Cancer Biotherapy and Radiopharmaceuticals · 2024

DOI: 10.1089/cbr.2023.0186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2024. Verfasst von Siyuan Fu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shang…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Methyltransferases, Disease Progression. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMethyltransferasesDisease ProgressionFragile X Messenger Ribonucleoprotein 1HumansPrognosisMiceAnimalsMaleFemaleMiddle AgedCell ProliferationCell Line, TumorMice, Nude

Stichwörter der Autor:innen

FMRPMETTL3growthhepatocellular carcinomainvasion

Substanzen

MethyltransferasesFragile X Messenger Ribonucleoprotein 1METTL3 protein, human

Autor:innen und Institutionen

  • The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China.

ORCID-Profile: Fangming Gu

Zitieren

APA

Fu, S., Sun, D., Wang, Z., Zhu, P., Ding, W., Huang, J., Guo, X., Yang, Y., & Gu, F. (2024). METTL3-Mediated m 6 A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2023.0186

Vancouver

Fu S, Sun D, Wang Z, Zhu P, Ding W, Huang J, et al. METTL3-Mediated m 6 A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis. Cancer Biotherapy and Radiopharmaceuticals. 2024. doi:10.1089/cbr.2023.0186

BibTeX
@article{Fu2024,
  author = {Fu, Siyuan and Sun, Dapeng and Wang, Zongyan and Zhu, Peng and Ding, Wenbin and Huang, Jian and Guo, Xinggang and Yang, Yun and Gu, Fangming},
  title = {METTL3-Mediated m 6 A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis},
  journal = {Cancer Biotherapy and Radiopharmaceuticals},
  year = {2024},
  doi = {10.1089/cbr.2023.0186}
}
Kostenlos starten →